Squarepoint Ops LLC Invests $671,000 in Organon & Co. (NYSE:OGN)

Squarepoint Ops LLC acquired a new stake in Organon & Co. (NYSE:OGN) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 32,408 shares of the company’s stock, valued at approximately $671,000.

A number of other institutional investors have also modified their holdings of OGN. Mercer Global Advisors Inc. ADV raised its position in Organon & Co. by 1.8% in the second quarter. Mercer Global Advisors Inc. ADV now owns 31,086 shares of the company’s stock valued at $674,000 after purchasing an additional 546 shares during the period. Ballentine Partners LLC raised its holdings in shares of Organon & Co. by 3.0% during the 2nd quarter. Ballentine Partners LLC now owns 19,105 shares of the company’s stock valued at $395,000 after buying an additional 552 shares during the period. Atomi Financial Group Inc. lifted its position in Organon & Co. by 1.8% during the 1st quarter. Atomi Financial Group Inc. now owns 32,858 shares of the company’s stock worth $618,000 after acquiring an additional 593 shares in the last quarter. Bill Few Associates Inc. boosted its holdings in Organon & Co. by 5.4% in the 2nd quarter. Bill Few Associates Inc. now owns 12,218 shares of the company’s stock worth $253,000 after acquiring an additional 621 shares during the period. Finally, GAMMA Investing LLC grew its position in Organon & Co. by 19.2% in the second quarter. GAMMA Investing LLC now owns 4,036 shares of the company’s stock valued at $84,000 after acquiring an additional 649 shares in the last quarter. Hedge funds and other institutional investors own 77.43% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. Evercore ISI upgraded shares of Organon & Co. to a “strong-buy” rating in a research note on Wednesday, September 18th. JPMorgan Chase & Co. downgraded Organon & Co. from a “neutral” rating to an “underweight” rating and raised their target price for the company from $18.00 to $20.00 in a research note on Friday, September 6th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $21.00.

Organon & Co. Price Performance

Shares of OGN stock opened at $18.11 on Wednesday. The firm has a fifty day moving average of $20.44 and a two-hundred day moving average of $20.17. The firm has a market cap of $4.66 billion, a P/E ratio of 4.43, a P/E/G ratio of 0.82 and a beta of 0.84. Organon & Co. has a 1-year low of $10.84 and a 1-year high of $23.10. The company has a debt-to-equity ratio of 60.05, a current ratio of 1.64 and a quick ratio of 1.17.

Organon & Co. (NYSE:OGN) last posted its quarterly earnings results on Tuesday, August 6th. The company reported $1.12 EPS for the quarter, topping analysts’ consensus estimates of $1.08 by $0.04. Organon & Co. had a negative return on equity of 840.29% and a net margin of 15.76%. The business had revenue of $1.61 billion during the quarter, compared to the consensus estimate of $1.61 billion. During the same period last year, the firm earned $1.31 earnings per share. The company’s revenue for the quarter was down .1% compared to the same quarter last year. As a group, research analysts anticipate that Organon & Co. will post 4.14 earnings per share for the current fiscal year.

Organon & Co. Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, September 12th. Investors of record on Friday, August 16th were given a dividend of $0.28 per share. This represents a $1.12 annualized dividend and a dividend yield of 6.19%. The ex-dividend date was Friday, August 16th. Organon & Co.’s dividend payout ratio is currently 27.38%.

Organon & Co. Company Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.